MaaT Pharma Says FDA Requires No Additional Nonclinical Safety Studies for MaaT034

• MaaT Pharma received FDA feedback supporting MaaT034’s proposed development approach for solid tumors, subject to review of a full investigational new drug application.
• The FDA required no additional nonclinical safety studies but requested further information from completed studies; final meeting minutes remain pending.
• Preclinical findings suggest the microbiome-based candidate could enhance antitumor activity when combined with immune checkpoint inhibitors.
• A first-in-human trial could begin in late 2027, subject to regulatory authorization and adequate financing.
• With cash runway estimated through December 2026, the company is exploring investor funding and strategic partnerships to support clinical development.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Maat Pharma SA published the original content used to generate this news brief via Business Wire (Ref. ID: 20261019365175) on October 19, 2026, and is solely responsible for the information contained therein.